Sensome Announces Enrollment Completion in First-in-Human Study of In Situ Tumor Detection System for Lung Cancer
“PARIS–(BUSINESS WIRE)–#bronchoscopy–Sensome, the pioneer of microsensing technology for real-time, intra-operative tissue analysis, announced today it has completed enrollment in the first-in-human INSPECT study of its novel technology, being developed to detect cancerous tissue in situ during transbronchial biopsy of endobronchial and peripheral tumors.”
Stanford Study Links Immune Cell Spatial Patterns to Immunotherapy Outcomes in Lung Cancer
“A recent study conducted by researchers at Stanford University has identified a potential link between the spatial organization of immune cells within tumors and patient responses to immunotherapy for non-small-cell lung cancer. The findings suggest that the arrangement of immune cells around tumors could serve as a more accurate predictor of treatment outcomes compared to current biomarker tests.”
Operation Hope: How Federally Funded Research Helped Navy Veteran Beat Lung Cancer and Pneumonitis
“Newswise — It started with a bit of blood. In April 2013, then 68-year-old John Ryan checked in with his primary care physician after he suddenly began to cough up trace amounts of blood. One emergency room trip and several tests later, the 30-year Navy veteran was told to prepare for his toughest battle yet: stage 4 non-small-cell lung cancer, adenocarcinoma.”
EQUAL Study Launches Lung Cancer Screening Trial for People at High Risk
“Dana-Farber Cancer Institute researchers have launched a study of a novel, homegrown blood test in hopes of identifying people who are at an elevated risk of lung cancer – despite never having used tobacco – and screen them for the disease. The team, led by principal investigator and thoracic oncologist Narjust Florez, MD, associate director of Dana-Farber’s Cancer Care Equity Program, designed the study in response to rising rates of lung cancer in younger people and prevalence in individuals of Asian or Hispanic/Latinx descent who have never used tobacco.”
American Lung Association Addresses Recent Study About Radiation in CT Scans
“Last month, JAMA Internal Medicine published an article, Projected Lifetime Cancer Risks From Current Computed Tomography Imaging, that uses risk modeling to suggest that radiation from Computed Tomography (CT) scans would contribute to a significant amount of new cancer diagnosis.”
New biomarker may guide best use of KRAS inhibitors in lung cancer
“Key Takeaways: Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib. This biomarker may help physicians determine those most likely to benefit from sotorasib and those who may need alternative or combination therapies. TTF-1 is a readily available biomarker commonly used for lung cancer diagnostics.”
Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-Seeking
“After observing minimal recurrence following 70 double lung resections within Northwestern’s Double lung transplant REgistry Aimed for lung-limited Malignancies (DREAM) program, Ankit Bharat, MBBS, suggested that stage IV lung cancer may be curable during an interview with CancerNetwork®.”
Western North Carolina VA Leads in Early Lung Cancer Detection
“A hybrid operating room at the medical center allows for real time imaging to spot early-stage lung cancers and then remove them in a minimally invasive procedure. This cuts time between assessment, testing and, treatment—when it comes to cancer, time is everything.”
Merck, Daiichi pull approval application for ADC in lung cancer
“Merck & Co. and Daiichi Sankyo have withdrawn an approval application in the U.S. for a lung cancer drug at the center of a multibillion-dollar alliance the companies formed two years ago. In a short statement Thursday, the companies said they’ve pulled a Food and Drug Administration submission for an experimental therapy known as patritumab deruxtecan.”
UNMC researchers find promising target for lung cancer treatment
“A UNMC research team, including postdoctoral research associate Muthamil Iniyan Appadurai, PhD, and assistant professor Imayavaramban Lakshmanan, PhD, has identified a novel mechanism that may help explain not only how lung cancer evades the immune system but also uncovered a potential new therapeutic target.”
To get more women screened for lung cancer, combine it with a mammogram
“When it comes to cancer prevention, certain body parts get more due diligence than others. Lung cancer is the leading cancer killer of both men and women in the U.S., but you wouldn’t know it by the attention it receives. Only 5% of those eligible for lung cancer screening receive the recommended imaging. In contrast, 72% of women eligible for breast cancer screening undergo regular mammograms, and a similar percentage of eligible men and women are screened for colon cancer. That’s despite the fact that lung cancer kills around 50% more women than breast cancer every year in the U.S.”
Molecularly Guided Chemotherapy Boosts Survival in Early NSCLC
“The interim analysis of the international, multicenter, prospective, randomized AIM-HIGH trial (NCT01817192) revealed a substantial improvement in disease-free survival (DFS) at 24 months for patients with stage IA to IIA nonsquamous non–small cell lung cancer (NSCLC) identified as high risk by a 14-gene molecular assay who received adjuvant chemotherapy, according to data presented at the 2025 American Society of Clinical Oncology Annual Meeting press briefing on Tuesday, May 27, 2025.”
New York Lawmakers Remove Barriers to Lung Cancer Screening, Passing A1195-A / S2000-A
“Earlier today, the New York State Senate voted to remove barriers to lung cancer screening in New York State, passing critical legislation to better equip New Yorkers to detect and treat lung cancer. S2000-A / A1195-A ensures comprehensive insurance coverage for lung cancer screening and eliminates cost sharing for recommended lung cancer screening, follow-up scans and diagnostic tests for asymptomatic individuals by all payers in the state.”
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
“TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC. TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting. NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting.”
Adagrasib/Pembrolizumab Yields Improved Survival in KRAS G12C-Mutated NSCLC
“Adagrasib (Krazati) plus pembrolizumab (Keytruda) improved efficacy for patients with KRAS G12C-mutated non–small cell lung cancer (NSCLC), according to results from the phase 2 KRYSTAL-7 trial (NCT04613596) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.”
Amgen drug cuts small cell lung cancer death risk by 40%
“June 2 (Reuters) – Amgen’s (AMGN.O), opens new tab Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data from a late-stage trial presented at a major medical meeting on Monday. The Phase 3 trial of 509 patients showed that Imdelltra extended median overall survival by more than five months to 13.6 months, compared with 8.3 months for standard-of-care chemotherapy, the company said.”
Immunotherapy before surgery improves lung cancer survival in global clinical trial led by Irish cancer specialist
“Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment.”
